Methods	Six-week randomised, double-blind study.
Participants	Outpatients fulfilling DSM-III criteria for unipolar major depression, with a score of at least 20 on the HDRS and Raskin Depression Scale score of at least 8 and equal or greater to the Covi Anxiety score. Age range: 18-70. Exclusion criteria: pregnancy, non-contrception, serious suicide risk, organic brain syndrome, schizophrenia, seizures, drug or alcohol abuse within the past year, controindication to imipramine
Interventions	Fluoxetine: 61 participants. Imipramine: 58 participants. Placebo: 59 participants. Fluoxetine dose range: not stated Imipramine dose range: not stated.
Outcomes	Hamilton Rating Scale for Depression, Raskin Depression Scale, Covi Anxiety Scale, CGI, SCL-58, PGI
Notes	Improvement: a moderately or markedly improved on the CGI or a decrease of at least 50% on the total HDRS score. Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear